A guide to KEYTRUDA® (pembrolizumab) and how to manage immune-mediated adverse events
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Download this slide deck for information on the MOA of KEYTRUDA, dosing and administration, and the management of immune-related adverse events.
Please ensure you click the relevant Great Britain or Northern Ireland version of the material above, depending on the location in which you practise.
More information about KEYTRUDA® (pembrolizumab):
Related content
Supporting documentation
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website
